• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biomarin Pharmaceuticals (NQ: BMRN )

    82.46 +0.29 (+0.35%)
    Streaming Delayed Price Updated: 9:35 AM EDT, Apr 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 45,387
    Open 82.33
    Bid (Size) 82.30 (1)
    Ask (Size) 82.49 (4)
    Prev. Close 82.17
    Today's Range 81.59 - 82.55
    52wk Range 76.02 - 99.56
    Shares Outstanding 183,352,255
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
    Via Benzinga

    Performance

    YTD
    -15.90%
    -15.90%
    1 Month
    -6.02%
    -6.02%
    3 Month
    -9.63%
    -9.63%
    6 Month
    +0.60%
    +0.60%
    1 Year
    -11.33%
    -11.33%

    More News

    Read More
    3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
    Via InvestorPlace
    Looking Into Biomarin Pharmaceutical's Recent Short Interest
    Via Benzinga
    The Latest Analyst Ratings For Biomarin Pharmaceutical
    Via Benzinga
    Recap: Biomarin Pharmaceutical Q4 Earnings
    Via Benzinga
    BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
    Via Chartmill
    While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable.
    Via Chartmill
    4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
    Via Benzinga
    Earnings Outlook For Biomarin Pharmaceutical
    Via Benzinga
    Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
    Via Chartmill
    7 Biotech Stocks Fighting America’s Deadliest Diseases
    Via InvestorPlace
    3 No-Brainer Stocks to Buy With $200 Right Now
    Via The Motley Fool
    4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
    Via InvestorPlace
    4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
    Via InvestorPlace
    3 Promising Biotech Stocks Flying Under the Radar
    Via InvestorPlace
    BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
    Via Investor's Business Daily
    Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
    Via The Motley Fool
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.